文献速递胸部肿瘤

四种PD-L1免疫组化检测在肺癌中的比较

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2017-11-23

该研究对368例切除肺癌组织芯片连续切片,按说明书分别用22C3、28-8(Dako Link 48)和SP142、SP263(Ventana Benchmark Ultra)染色,并开发22C3在Ventana平台使用的方案。结果显示四种检测的肿瘤细胞和免疫细胞染色均存在差异(p < 0.001),仅22C3与28-8一致性较高(ICC = 0.812),免疫细胞一致性差(ICC = 0.212)。结论认为除28-8与22C3外,其余检测不可互换使用。

要点

  • 四种PD-L1免疫组化检测的染色结果存在显著差异(p < 0.001)。
  • 仅22C3与28-8肿瘤细胞评分一致性较高(ICC = 0.812)。
  • 按临床 cutoff 二分后,两两比较一致性差至中等(κ = 0.196-0.578)。

核心结论

  • 除28-8与22C3外,四种PD-L1免疫组化检测在临床实践中不能互换使用。
  • 成功开发了22C3抗体在Ventana Benchmark Ultra平台使用的方案。

研究设计与样本

  • 研究类型:检测方法比较研究。
  • 样本:368例切除肺癌组织芯片连续切片。
  • 检测平台:22C3和28-8在Dako Link 48平台,SP142和SP263在Ventana Benchmark Ultra平台,严格按产品说明书操作。
  • 额外开发22C3在Ventana Benchmark Ultra平台的染色方案。

主要发现

  • 四种检测的平均肿瘤细胞和免疫细胞染色存在差异(p < 0.001)。
  • 22C3与28-8之间差异无统计学意义。
  • 肿瘤细胞评分一致性良好(ICC = 0.674),排除SP142后ICC = 0.755,22C3与28-8最高(ICC = 0.812)。
  • 免疫细胞染色一致性差(ICC = 0.212)。
  • 按临床相关cutoff二分后,两两比较一致性差至中等(κ = 0.196-0.578),阳性符合率15.1%至90.0%。

临床怎么用

  • 临床使用PD-L1免疫组化检测时,应明确所用抗体与平台,除28-8与22C3外不宜互换。
  • 22C3可在Ventana Benchmark Ultra平台使用,有助于克服实施障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Four different programmed death ligand 1 immunohistochemical assays are approved or in development as companion or complementary diagnostics to different immunotherapeutic agents in lung carcinoma. We sought to determine whether these assays are technically equivalent and whether one antibody can be used on an alternate staining platform. METHODS: Serial sections of tissue microarrays constructed from 368 cases of resected lung cancer were stained for 22C3 and 28-8 on the Dako Link 48 platform (Dako, Carpinteria, Ca) and for SP142 and SP263 on the Ventana Benchmark Ultra platform (Ventana Medical Systems, Tucson, AZ) strictly as per product insert. A protocol was developed to use the 22C3 antibody on the Ventana Benchmark Ultra platform. RESULTS: Differences in mean tumor cell and immune cell staining were observed between the four assays (p < 0.001). Differences between 22C3 and 28-8 were not statistically significant. Concordance of tumor cell scores was good (intraclass correlation coefficient [ICC] = 0.674), particularly when SP142 was excluded as an outlier (ICC = 0.755). The highest concordance was seen between 22C3 and 28-8 (ICC = 0.812). Concordance was poor for immune cell staining (ICC = 0.212). When dichotomized according to clinically relevant cutoffs, pairwise comparisons showed poor to moderate concordance (κ = 0.196-0.578), with positive percent agreement ranging from 15.1% to 90.0%. The 22C3 antibody performed comparably on the Dako Link 48 platform and the alternate Ventana Benchmark Ultra platform (ICC = 0.921, κ = 0.897). CONCLUSIONS: Concordance between the four programmed death ligand 1 immunohistochemical assays when performed and scored as intended show that apart from 28-8 and 22C3, they cannot be used interchangeably in clinical practice. A protocol was successfully developed to use 22C3 on an alternate platform, which may help to overcome some barriers to implementation.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Hendry S, Byrne DJ, Wright GM, et al. Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer. J Thorac Oncol. 2017. PMID: 29175115. doi:10.1016/j.jtho.2017.11.112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。